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Abstract
Rationale: Early empirical antimicrobial treatment is frequently
prescribed to critically ill patients with coronavirus disease
(COVID-19) based on Surviving Sepsis Campaign guidelines.
Objectives: We aimed to determine the prevalence of early
bacterial identification in intubated patients with severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia, as
compared with influenza pneumonia, and to characterize its
microbiology and impact on outcomes.
Methods: A multicenter retrospective European cohort was
performed in 36 ICUs. All adult patients receiving invasivemechanical
ventilation .48 hours were eligible if they had SARS-CoV-2 or
influenza pneumonia at ICU admission. Bacterial identification was
defined by a positive bacterial culture within 48 hours after intubation
in endotracheal aspirates, BAL, blood cultures, or a positive
pneumococcal or legionella urinary antigen test.
Measurements and Main Results: A total of 1,050 patients were
included (568 in SARS-CoV-2 and 482 in influenza groups). The
prevalence of bacterial identification was significantly
lower in patients with SARS-CoV-2 pneumonia compared with
patients with influenza pneumonia (9.7 vs. 33.6%; unadjusted odds
ratio, 0.21; 95% confidence interval [CI], 0.15–0.30; adjusted odds
ratio, 0.23; 95% CI, 0.16–0.33; P, 0.0001).
Gram-positive cocci were responsible for 58% and 72% of
coinfection in patients with SARS-CoV-2 and influenza
pneumonia, respectively. Bacterial identification was associated
with increased adjusted hazard ratio for 28-day mortality in
patients with SARS-CoV-2 pneumonia (1.57; 95% CI, 1.01–2.44;
P= 0.043). However, no significant difference was found in the
heterogeneity of outcomes related to bacterial identification
between the two study groups, suggesting that the impact of
coinfection on mortality was not different between patients
with SARS-CoV-2 and influenza.
Conclusions: Bacterial identification within 48 hours after
intubation is significantly less frequent in patients with SARS-
CoV-2 pneumonia than patients with influenza pneumonia.
Clinical trial registered with www.clinicaltrials.gov
(NCT 04359693).
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By spring 2021, the ongoing coronavirus
disease (COVID-19) pandemic, caused by
severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), has affected
more than 130 million people, resulting in
more than 2,800,000 deaths worldwide (1).
Approximately 20% of hospitalized patients
are admitted to the ICU because of acute
respiratory failure (2). A large proportion of
these critically ill patients require intubation,
and among them, almost half will
eventually die, with high variability
depending on patients’ age and geographic
location (2–4).
For the sickest patients (i.e., those
invasively mechanically ventilated), the
Surviving Sepsis Campaign COVID-19 panel
suggested, inMarch 2020, the use of empirical
antibiotic therapy to reduce the mortality
associated with potential early bacterial
coinfection, with necessary daily assessment
for deescalation according to microbiology
results and thepatient’s clinical status (5). This
recommendation was based on low-quality
evidence upon extrapolation of data from
other viral pneumonias, particularly influenza
(6, 7). Indeed, bacterial coinfection is
commonly reported in critically ill patients
admitted for either seasonal or pandemic
influenza (8–10). The copathogenesis of
influenza viruses and bacteria in the lung is
characterized by complex interactions
between coinfecting pathogens and the host,
leading to the disruption of physical barriers,
dysregulation of immune responses, and, at
last, bacteria adhesion, overgrowth, and
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additional immune-mediated host damage
(11, 12). As a result, bacterial coinfection may
promote a greater severity of viral infection, as
supported by few autopsy series of fatal
influenzacasesduringpastpandemics(11,13),
and has been reported as a major cause of
morbidity and mortality among critically ill
patients (9).
However, data on the prevalence of early
bacterial coinfection in critically ill patients
withCOVID-19 are limited. In the last update
of the livingmeta-analysis from Langford and
colleagues (14), including 7,107 patients with
COVID-19, bacterial coinfection was
identified in 4.9% of hospitalized patients on
admission (95% confidence interval [CI],
2.6–7.1), althoughthereportedratewashigher
in ICU settings at 16.0% (95% CI, 11.6–20.4).
However, few critically ill patients were
included, illness severity was heterogeneous,
and healthcare-associated infections were
combined in the ICU subgroup analysis.
Recently, two French cohorts including,
respectively, 47 and 83 critically ill patients
under invasive mechanical ventilation both
reported a 28% rate of bacterial coinfection
upon ICU admission (15, 16).
Giventhescarceandconflictingavailable
data, we conducted this study to compare the
prevalence of bacterial identification within
thefirst2daysafter intubationinpatientswith
SARS-CoV-2 or influenza pneumonia and to
characterize the microbiological findings and
the impact on clinical outcomes of bacterial
coinfection. Some of the results of this study
have been previously reported in the form of
an abstract (17).
Methods
Study Design and Population
This study is a preplanned ancillary analysis of
the COVID-19 and ventilator-assocaited
pneumonia (coVAPid) multicenter
retrospective observational cohort study (18),
conducted in 36 ICUs inEurope (28 centers in
France, 3 in Spain, 3 in Greece, 1 in Portugal,
and 1 in Ireland), selected by invitation.
Eligibility criteria included age equal to or
above 18 years, the need for invasive
mechanical ventilation for more than 48
hours, and the presence at ICU admission of
either SARS-CoV-2 pneumonia or influenza
pneumonia. Patients were excluded if a viral
respiratory infection other than SARS-CoV-2
or influenza was simultaneously diagnosed at
ICU admission.
Participating centers retrospectively
collected data from consecutive patients
admitted to their ICU with SARS-CoV-2
(starting at the beginning of the COVID-19
pandemic in each center) or influenza A or B
pneumonia (starting from the last patients
admitted with this diagnosis in 2020 and
going back to previous seasons if necessary).
Each center was asked to include the same
number of patients (10–20) in eachof the two
study groups. Viral infections were
confirmedby a positive result of PCRassay of
nasopharyngeal or respiratory secretions
samples.
The Ethics Committee and Institutional
Review Board of the Lille University Hospital
approved the study protocol (Comite de
Protection des Personnes Ouest VI; approved
by April 14, 2020; registration number
RIPH:20.04.09.60039) as minimal-risk
research using data collected for routine
clinical practice and waived the need for
informed consent from individual patients.
Patients (or their proxies) received written
information about the study and could refuse
to participate. The study was registered at
ClinicalTrials.gov (NCT 04359693).
Definitions
Early bacterial identification was defined by a
positive culture of one or more bacterial
pathogenswithin48hoursafter intubationina
respiratorytractsample(endotrachealaspirate
or BAL), blood, or a positive Streptococcus
pneumoniae or Legionella pneumophila
urinary antigen test. Microbiological
identification and susceptibility tests were
performed using standard culture-dependent
methods. Multidrug-resistant isolates were
definedasacquirednonsusceptibility toat least
one agent in three or more antimicrobial
categories (19). Initial antibiotic treatmentwas
considered as appropriate when at least one
antibiotic matching the in vitro susceptibility
of the pathogen causing bacterial coinfection
was given to treat this infection (20).
Outcomes
The primary outcome of our study was the
prevalence of early bacterial identification
among patients admitted to the ICU with
SARS-CoV-2 pneumonia compared with
influenza pneumonia. The secondary
endpoints included the etiology andoutcomes
of bacterial coinfection, including mechanical
ventilation duration, ICU length of stay, and
28-day all-cause mortality.
Statistical Analysis
Wecompared the prevalence of early bacterial
identificationbetweenthe twostudygroupsby
using logistic regression analysis before and
after adjustment for the followingprespecified
confounders: simplified acute physiology
score (SAPS) II, chronic obstructive
pulmonary disease (COPD), chronic
respiratory failure, immunosuppression,
recent hospitalization, and antibiotic
treatment on ICU admission.
We assessed the association of early
bacterial identification with the patient’s
outcomes censored at 28 days (overall survival,
mechanical ventilation duration, and length of
ICU stay) using a Cox’s regression model
performed on the whole population (study
groups combined together). Cause-specific
hazard was calculated for mechanical
ventilation duration (considering extubation
alive as event of interest and death under
mechanical ventilation as competing event)
and for length of ICU stay (considering ICU
discharge alive as event of interest and death
duringICUascompetingevent)(21), including
study group, bacterial identification, and
interactionbetweenbacterial identificationand
studygroup. In each studygroup, hazard ratios
(HRs) for association of bacterial identification
withdifferent outcomeswerederived fromthis
model as effect sizes using linear contrast. The
associations were further adjusted for the
At a Glance Commentary
Scientific Knowledge on the
Subject: Prevalence of early bacterial
coinfection in hospitalized patients
with coronavirus disease (COVID-19)
seems low, but data regarding
critically ill patients are lacking.
What This Study Adds to the Field:
This multicenter retrospective cohort
study reports 9.7% bacterial
identification within 48 hours after
intubation in patients with severe acute
respiratory syndrome coronavirus 2
(SARS-CoV-2) pneumonia, which is
threefold lower than patients with
influenza pneumonia. Our findings
suggest that early empirical
antimicrobial treatment should be
carefully evaluated at ICU admission
after respiratory secretions sampling.
Further studies are needed to determine
whether antibiotic treatment should be
limited to the most severe patients.
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following prespecified confounders: sex, SAPS
II, bodymass index, MacCabe classification,
shock, acute respiratory distress syndrome
(ARDS), cardiac arrest, antibiotic treatment at
ICU admission, and ventilator-associated
pneumonia(treatedasatime-varyingvariable).
To avoid case deletion in multivariate
analyses because of the presence of missing
data in covariates, multivariable logistic and
Cox’s regressionmodels were performed after
handling missing data on a patient’s
characteristics at ICU admission by using a
multiple imputation procedure (22).
In addition to the main analyses, we
performed two post hoc sensitivity analyses to
assess, according to study group, the
prevalence of bacterial identification and
association of coinfection with the patient’s
outcomes in two more stringent
subpopulations of interest. First, patients
intubated more than 48 hours after hospital
admission were excluded, focusing on the
occurrence and prognosis of community-
acquired bacterial coinfections only. Second,
we excluded patients from whom no
respiratory sample could be collected within
48 hours of intubation because of a lack of
productive tracheal secretions for noninvasive
sampling via endotracheal aspirate or
unavailabilityof an invasive samplingmethod.
Statistical testing was performed at the
two-tailed a level of 0.05. Data were analyzed
using the SAS software package, release 9.4
(SAS Institute). The statistical analysis is fully
detailed in the online supplement.
Results
A total of 1,050 patients (568 in SARS-CoV-2
pneumonia group and 482 in influenza
pneumonia group) admitted to ICU between
March 2016 andMay 2020 were included in
the 36 participating centers (Figure 1).
Influenza A and B were diagnosed in 421




Percentage of men, body mass index, and
percentage of ARDS as the cause for ICU
admission were higher in the SARS-CoV-2
pneumonia group than in influenza
pneumonia group. SAPS II, sequential organ
failure assessment score, comorbidities scores,
chronic diseases (COPD, chronic respiratory
failure, immunosuppression, active smoking,
and alcohol abuse), rate of recent
hospitalization, and percentage of shock,
cardiac arrest, neurological failure, or acute
kidney injury as causes for ICU admission
were lower in the SARS-CoV-2 pneumonia
group than in the influenzapneumoniagroup.
Intubation occurred in the first 48 hours after
hospital admission in 68.4% of patients with
SARS-CoV-2 and 76.0% of patients with
influenza, respectively. Antibiotics on ICU





488 patients screened for eligibility
admitted from March 2016 to February 2020
482 patients included
568 patients analyzed (overall population)
 -359 patients < 48h hospital stay
(sensitivity analysis 1)
 - 411 patients with at least 1
respiratory sample (sensitivity analysis 2)
482 patients analyzed (overall population)
 - 341 patients < 48h hospital stay
(sensitivity analysis 1)
 - 425 patients with at least 1






24 (43.6%) dead at day 28 142 (27.7%) dead at day 28
513 (90.3%) with no
bacterial identification
320 (66.4%) with no
bacterial identification
85 (26.6%) dead at day 2847 (29.0%) dead at day 28
1 Patient excluded (0.1%)
 - influenza co-infection
6 Patients excluded (1.2%)
 - medical file unavailable
569 patients screened for eligibility
admitted from February 2020 to May 2020
Figure 1. Patient flowchart. SARS-CoV-2= severe acute respiratory syndrome coronavirus 2.
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Age, yr 64 (55–71) 62 (53–71) 0.044 12.7
Men 407/568 (71.7) 298/482 (61.8) ,0.001 21.1
Body mass index*, kg/m2 28.9 (25.8–33.3) 27.5 (23.3–32.3) ,0.001 30.0
Severity scores
SAPS II† 41 (32–55) 50 (39–64) ,0.001 48.5




475/543 (87.5) 324/456 (71.1) ,0.001 40.1
Fatal ,5 yr 62/543 (11.4) 114/456 (25.0)
Fatal ,1 yr 6/543 (1.1) 18/456 (3.9)
Charlson Comorbidity
Index§
3 (1–4) 3 (2–5) ,0.001 28.4
Chronic diseases
Diabetes mellitus 168/565 (29.7) 104/474 (21.9) 0.004 17.9
Chronic kidney disease 33/559 (5.9) 39/475 (8.2) 0.15 9.0
Heart disease 103/560 (18.4) 117/476 (24.6) 0.015 15.1
Chronic heart failure 21/558 (3.8) 37/475 (7.8) 0.005 17.3
COPD 37/560 (6.6) 129/475 (27.2) ,0.001 57.1
Chronic respiratory
failure
20/558 (3.6) 67/475 (14.1) ,0.001 37.7
Cirrhosis 8/559 (1.4) 16/475 (3.4) 0.039 12.7
Immunosuppression 52/559 (9.3) 107/479 (22.3) ,0.001 36.3
Active smoking 29/560 (5.2) 149/476 (31.3) ,0.001 71.9
Alcohol abuse 34/558 (6.1) 85/475 (17.9) ,0.001 36.9
Recent hospitalization
(,3 mo)
44/566 (7.8) 72/479 (15.0) ,0.001 23.0
Recent antibiotics (,3
mo)
74/567 (13.1) 95/477 (19.9) 0.003 18.6
Location before ICU
admission
Home 271/568 (47.7) 275/481 (57.2) 0.006 19.0
Hospital ward 215/568 (37.9) 157/481 (32.6)
Another ICU 82/568 (14.4) 49/481 (10.2)
Time from hospital to ICU
admission, d
1 (0–2) 0 (0–2) 0.015 15.5




1 (0–3) 1 (0–2) ,0.001 23.0
<48 h 359/525 (68.4) 341/449 (76.0) 0.009 16.9
Antibiotic treatment on
ICU admission
494/558 (88.5) 417/471 (88.5) 1.00 0.0
Causes for ICU
admission
Shock 102/557 (18.3) 210/470 (44.7) ,0.001 59.2
Acute respiratory failure 521/567 (91.9) 433/461 (90.2) 0.34 5.9
ARDS 386/563 (68.6) 220/469 (46.9) ,0.001 44.9
Neurological failure 26/548 (4.7) 69/465 (14.8) ,0.001 34.5
Cardiac arrest 3/547 (0.6) 25/465 (5.4) ,0.001 28.8
Acute kidney injury 96/567 (17.5) 133/480 (28.9) ,0.001 27.1
Definition of abbreviations: ARDS=acute respiratory distress syndrome; COPD=chronic obstructive pulmonary disease; SAPS II = simplified acute
physiology score II; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2; SOFA=sequential organ failure assessment.
Values are n/N (%) or median (interquartile range). McCabe classification of comorbidities and likelihood of survival: likely to survive.5 yr, 1–5 yr, or
,1 yr; chronic kidney disease: National Kidney Foundation Kidney Disease Outcome Quality Initiative (KDOQI CKD) classification stage 4 or 5
(creatinine clearance ,30 ml/mn); chronic heart failure: New York Heart Association class III or IV; heart disease: ischemic heart disease or atrial
fibrillation; cirrhosis: Child-Pugh score B or C; immunosuppression: hematological malignancy, allogenic stem cell transplant, solid cancer, organ
transplant, HIV, or immunosuppressive drugs; and antibiotic treatment on ICU admission: at least one dose of antibiotics in the first day of ICU stay.
More than one cause for ICU admission is possible.
*100 missing values (SARS-CoV-2, n=32; influenza, n=68).
†
66 missing values (SARS-CoV-2, n=43; influenza, n=21).
‡
25 missing values (SARS-CoV-2, n=21; influenza, n=4).
§
30 missing values (SARS-CoV-2, n=19; influenza, n=11).
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admission were reported in 88.5% of patients
in both groups (Table 1).
Prevalence of Early Bacterial
Identification
The prevalence of bacterial identification was
significantly lower in patients with SARS-
CoV-2 pneumonia than in patients with
influenza pneumonia (9.7% vs. 33.6%;
unadjustedOR, 0.21; 95%CI, 0.15–0.30;Table
2). This difference remained significant after
adjustment for the aforementioned baseline
relevant confounders (adjustedOR, 0.23; 95%
CI, 0.16–0.33; P, 0.0001). At least one
respiratory sample could be collected within
48 hours after intubation in 73.5% of patients
with SARS-CoV-2 and 89.5% of patients with
influenza. Antibiotic treatment was reported
at the time of sampling in 85.4% and 89.6% of
cases. Bacteria were mostly isolated on
endotracheal aspirate in coinfected patients
(see Table E1 in online data supplement).
Patientcharacteristicsat ICUadmissionandat
the time of bacterial identification
according to study group and bacterial
identification status are reported in Table
E2.Coinfected patients in the SARS-CoV-2
pneumonia group had a higher sequential
organ failure assessment score and higher
rates of shock andARDSonadmission than
noncoinfected patients. Furthermore, at
the time of diagnosis, among patients with
available data, coinfected patients showed
higher levels of procalcitonin than
noncoinfected patients (0.9 [0.3–4.3] vs.
0.5 [0.2–1.5] in the SARS-CoV-2 group and
6.4 [1.4–50.2] vs. 1.5 [0.5–9.8] in the
influenza group). Sensitivity analyses
regarding the prevalence of early bacterial
identification across study groups were
consistent with overall population results
(Table 2).
Microbiological Results
The majority of early bacterial identification
was related to gram-positive cocci (58% in the
SARS-CoV-2 group and 72% in the influenza
group), mostly Staphylococcus aureus
and Streptococcus pneumoniae. Among
gram-negative rods, Pseudomonas aeruginosa
andHaemophilus influenzaewere,
respectively, responsible for 11% and 9% of
episodes in patients with SARS-CoV-2 and
for 6% and 11% of episodes in patients with
influenza. Early bacterial coinfection was
polymicrobial in 9% and 7% of cases in the
SARS-CoV-2 and influenza groups,
respectively. The rate of patients with
coinfection owing to multidrug-resistant
bacteria was low (6% and 4%) in the two
study groups (Table 3). Initial antibiotic
treatment was appropriate in 38 of 54
(70.4%) and 125 of 158 (79.1%) coinfected
patients in the SARS-CoV-2 and influenza
groups, respectively.
Table 3. Microbiological Data
SARS-CoV-2
Pneumonia (n = 55)
Influenza Pneumonia
(n = 162)
Gram-positive cocci 32 (58.2) 116 (71.6)
Methicillin-sensitive Staphylococcus aureus 13 (23.6) 47 (29.0)
Methicillin-resistant Staphylococcus aureus 1 (1.8) 4 (2.5)
Staphylococcus other than aureus 1 (1.8) 2 (1.2)
Streptococcus pneumoniae 12 (21.8) 52 (32.1)
Other Streptococcus spp 4 (7.3) 10 (6.2)
Enterococcus spp 1 (1.8) 1 (0.6)
Gram-negative bacilli 23 (41.8) 45 (27.8)
Pseudomonas aeruginosa 6 (10.9) 10 (6.2)
Haemophilus influenzae 5 (9.1) 18 (11.1)
Moraxella catarrhalis 3 (5.5) 1 (0.6)
Enterobacter spp 2 (3.6) 1 (0.6)
Klebsiella pneumonia 2 (3.6) 3 (1.9)
Other Klebsiella spp 0 (0.0) 1 (0.6)
Serratia marcescens 2 (3.6) 0 (0.0)
Citrobacter spp 1 (1.8) 0 (0.0)
Proteus mirabilis 1 (1.8) 0 (0.0)
Acinetobacter baumannii 1 (1.8) 2 (1.2)
Escherichia coli 0 (0.0) 5 (3.1)
Morganella morganii 0 (0.0) 3 (1.9)
Stenotrophomonas maltophilia 0 (0.0) 1 (0.6)
Other 4 (7.3) 9 (5.6)
Polymicrobial 5 (9.1) 11 (6.8)
Multidrug-resistant isolates 3 (5.5) 6 (3.7)
Definition of abbreviation: SARS-CoV-2= severe acute respiratory syndrome coronavirus 2.
Values are n (%). More than one bacteria can be identified for each patient.
Table 2. Prevalence of Early Bacterial Identification




(95% CI) P Value*
Overall population 55/568 (9.7) 162/482 (33.6) 0.21 (0.15–0.30) 0.23 (0.16–0.33) ,0.0001
,48-h hospital stay† 29/359 (8.1) 129/341 (37.8) 0.14 (0.09–0.23) 0.15 (0.09–0.25) ,0.0001
At least one respiratory sample† 55/411 (13.4) 162/425 (38.1) 0.25 (0.17–0.36) 0.26 (0.18–0.39) ,0.0001
Definition of abbreviations: CI = confidence interval; OR=odds ratio; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.
Values are n/N (%).
*Adjusted for prespecified confounders simplified acute physiology score II, chronic obstructive pulmonary disease, chronic respiratory failure,
immunosuppression, recent hospitalization, and antibiotic treatment on ICU admission and calculated after handling missing values on covariates
by multiple imputation.
†Sensitivity analyses were performed among patients intubated in the first 48 hours after hospital admission (359/525 [68.4] in the SARS-CoV-2
group and 341/449 [76.0] in the influenza group) or in whom at least one respiratory sample could be collected within 48 hours of intubation (411/559
[73.5] in the SARS-CoV-2 group and 425/475 [89.5] in the influenza group).
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Impact on Outcomes
The difference in 28-day mortality rates
between patients with and without bacterial
identification was 16.0% (95% CI, 2.2 to 29.7)
in the SARS-CoV-2 pneumonia group and
2.5% (95% CI,26.1 to 11.0) in the
influenza pneumonia group (Figure 1).
Additional patient characteristics during
ICU stay, including 28-day outcomes, and
cumulative incidence of 28-day mortality,
extubation alive, and ICU discharge alive
according to study group and bacterial
identification status are reported in Table E3
and Figure 2.
Early bacterial identification was
associated with increased HR for 28-day
mortality in patients with SARS-CoV-2
pneumonia (unadjusted HR, 1.72; 95% CI,
1.11–2.66) but not in patients with
influenza pneumonia (unadjusted HR, 1.08;
95% CI, 0.75–1.55) (Figure 3). This
increased risk was still significant after
adjustment for potential confounders
(adjusted HR, 1.57; 95% CI, 1.01–2.44;
P=0.043). However, the P value for
heterogeneity with the influenza pneumonia
group was not significant (PHet= 0.16).
Furthermore, no significant association was
found between bacterial identification and
mechanical ventilation duration or length of
ICU stay in patients with SARS-CoV-2 or
influenza pneumonia.
Similar results regarding early bacterial
identification impact on outcomes according
to study groups were observed across
sensitivityanalyses, althoughdifferences in the
significance of size effects were observed
(Figures E2 and E3). Antibiotic treatment on
ICU admission had no significant impact on
the association of bacterial identification with
28-day all-cause mortality in the two study
groups (see Figure E4).
Discussion
Our study reports a threefold lower prevalence
of bacterial identification among patients with
SARS-CoV-2 within 48 hours after intubation
compared with patients with influenza
pneumonia. Gram-positive cocci, mostly S.
aureusandS.pneumoniae,were responsible for
the majority of bacterial coinfections. Early
bacterial identification was associated with
increased risk for 28-day mortality in patients
with SARS-CoV-2 pneumonia. However, no
significant difference was found in
heterogeneity of outcomes related to bacterial
identification between the two study groups,
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Figure 2. Cumulative incidence of (A) 28-day mortality, (B) extubation alive, and (C) and ICU discharge alive according to study groups (SARS-CoV-
2 pneumonia vs. influenza pneumonia) and early bacterial identification. Time axis origin is the day of intubation. SARS-CoV-2=severe acute
respiratory syndrome coronavirus 2.
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mortality was not different between patients
with SARS-CoV-2 and influenza.
To date, the absence of reliable estimates
of the prevalence of early bacterial coinfection
together with their challenging diagnosis,
namely, the inability to formally exclude
bacterial involvement,promotedawidespread
prescribing of systematic empirical
antimicrobial treatment in patients admitted
to ICU for SARS-CoV-2 infection. The use of
broad-spectrum antibiotics is reported in 72%
of hospitalized patients infected with SARS-
CoV-2 (23), and there arehigher rates, close to
90%,amongcritically illpatients(2,24)despite
limited available microbiological data. To the
best of our knowledge, this is the largest study
examining the prevalence of early bacterial
identificationinintubatedpatientswithSARS-
CoV-2 pneumonia compared with influenza
pneumonia. Inaddition,strengthsofourstudy
include themulticenter design, the choice of a
relevant control group, the defined timing of
bacterial isolation, and the robust adjustment
for confounding factors.
The34% rate of bacterial identification in
patients with influenza pneumonia is roughly
consistent with previous data from several
ICU cohorts, reporting 17–30% of coinfected
patients on admission, considering that all
included patients were not intubated (8–10).
Coinfection was unsurprisingly caused by S.
pneumoniae, S. aureus, andH. influenzae,
although the proportion of P. aeruginosawas
lower than expected (8, 9). The lower rate of
bacterial identification inpatientsadmitted for
COVID-19 could be explained by fewer
underlying respiratory conditions, such as
COPD and chronic respiratory failure,
associated with a risk of prior bronchial
colonization as well as less
immunosuppression, healthcare exposure,
andmultiple organ failure at admission in the
SARS-CoV-2 pneumonia group compared
with the influenza pneumonia group.
However, careful adjustment for these
confoundingfactorswasperformed.Although
both viral respiratory infections, COVID-19
differs from influenza in many ways by
activating distinct immune-response
pathways (25, 26) and having specific gut
microbial signature (27) and specific
pulmonary histopathology characterized by
severe endothelial injury, thrombosis, and
vascular angiogenesis (28, 29). Future research
will undoubtedly shed light on SARS-CoV-2
and bacteria interactions and explain the
resulting risk for bacterial coinfection.
Therateofearlybacterial identificationin
patients with SARS-CoV-2 pneumonia is
much lower than the reported prevalence of
28% at ICU admission in two recent cohorts
(15, 16). These studies were monocentric and
included a small number of patients with
SARS-CoV-2 without a control group. Both
respiratory multiplex PCR and culture were
used, which could explain the higher rate of
coinfection diagnosis. Furthermore, the
absence of a standardized protocol for
microbiological sampling after intubation and
the exposure to antibiotics at the time of
collection might have led to an
underestimation of the rate of coinfected
Unadjusted
Outcomes Disease groups HR (95% CI)
Overall survival SARS-CoV-2 1.72 (1.11 to 2.66)
1.08 (0.75 to 1.55)
0.94 (0.63 to 1.39)
1.21 (0.95 to 1.54)
0.94 (0.61 to 1.44)










Adjusted HR (95% CI)
10.0
0.24
1.57 (1.01 to 2.44)
1.04 (0.72 to 1.50)
0.02 (0.68 to 1.51)
1.23 (0.96 to 1.58)
0.99 (0.64 to 1.52)
1.20 (0.92 to 1.58)
Favors a decrease in
 Survival
 MV duration
 Length of ICU stay
Favors an increase in
 Survival
 MV duration
















Length of ICU stay
P-Value P Het
Adjusted
HR (95% CI) P-Value P Het
Figure 3. Association of early bacterial identification with 28-day outcomes according to study groups (SARS-CoV-2 pneumonia and influenza
pneumonia). HRs were calculated using cause-specific proportional hazard models by considering mortality as a competing event for mechanical
ventilation and length of ICU stay. Adjusted HRs were calculated by including sex, simplified acute physiology score II, body mass index, MacCabe
classification, shock, acute respiratory distress syndrome, cardiac arrest, antibiotic treatment on ICU admission, and ventilator-associated
pneumonia (treated as time-varying variable) as prespecified covariates in Cox’s models (after handling missing values by multiple imputation). An
HR.1 indicates a decrease in survival (i.e., an increased risk for mortality), MV duration (i.e., an increased risk for extubation alive), and ICU length
of stay (i.e., an increased risk for discharge alive), and an HR,1 indicates an increase in survival (i.e., a decreased risk for mortality), MV duration
(i.e., a decreased risk for extubation alive), and ICU length of stay (i.e., a decreased risk for discharge alive). The event of interest for survival is a
pejorative event (death), whereas for MV duration and ICU length of stay, the event of interest is a positive event (extubation or discharge alive).
Consequently, the detrimental effect of bacterial identification on each outcome was associated with an HR. 1 for overall survival but with an HR, 1
for MV duration and ICU length of stay. P Het indicates the P value for heterogeneity in association of bacterial identification and 28-day outcomes
across study groups (SARS-CoV-2 pneumonia vs. influenza pneumonia). CI = confidence interval; HR=hazard ratio; MV=mechanical ventilation;
SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.
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patients in our study, especially in patients
with COVID-19. In the context of the heavy
strain on healthcare systems, in overwhelmed
ICUs, routine microbiological investigations
might have been reduced because of extreme
workloads or even constrained by the fear
of exposure of caregivers to potential
aerosolization of SARS-CoV-2. In our study,
only 74% of patients with SARS-CoV-2 had at
leastonerespiratorysamplecollectedwithin48
hours after intubation versus 90% of patients
with influenza, whereas antibiotic exposure at
the time of microbiological sampling was
reported in85%and90%of cases, respectively.
However, sensitivity analysis excluding
patients without respiratory samples showed
similar findings regarding the prevalence of
bacterial identification across study groups.
Furthermore, all analyseswere adjusted on the
presence of antibiotic treatment on ICU
admission.
Time from hospital admission to
bacterial isolation, allowing for the
classification of documented early bacterial
coinfection in community- or hospital-
acquired infection, might have impacted the
coinfection rate in our study, assuming the
time-dependent process of bacterial airway
colonization after severe viral infection.
However, the majority of included patients
wereadmitted to the ICUwithin48hoursafter
hospital admission (79% in the SARS-CoV-2
and 82% in the influenza group). Data on
bacterial identification prevalence in
sensitivity analysis performed among patients
intubated within 48 hours after hospital
admission were also consistent with whole
population findings.
The bacteria responsible for early
coinfection in patients with SARS-CoV-2
pneumonia were the same as in patients with
influenza pneumonia: S. aureus, S.
pneumoniae,P. aeruginosa, andH. influenzae,
which is overall in line with previous
observations (14–16). Appropriate early
antibiotic treatment was reported in 70% and
79% of coinfection episodes among patients
with SARS-CoV-2 and influenza pneumonia,
respectively. However, early antibiotics on
ICU admission did not significantly modify
the impactofbacterial identificationon28-day
mortality across study groups.
We found no impact of early bacterial
identification on clinical outcomes among
patients with influenza pneumonia, but the
direct role played by bacterial coinfection on
morbidity and mortality in these populations
hasbeenpreviouslydifficult toestimate (8,10).
Similarly, the increased mortality risk
associated with bacterial identification among
patients with SARS-CoV-2 pneumonia could
not be confirmed in sensitivity analyses.
However, despite careful adjustments, our
analyses might have missed some residual
confounders. Furthermore, the number of
patients with bacterial identification in the
SARS-CoV-2 group was relatively small, and
our study might have been underpowered to
detect a significant difference in this subgroup
regarding secondary outcomes. Larger studies
are needed to explore the impact of early
bacterial coinfection on clinical outcomes in
patients with COVID-19.
Our results have potentially important
implications on the empirical antibiotic
strategyof patientswithCOVID-19 in thefirst
days after their intubation, as they suggest that
the majority of these patients may not require
antimicrobial treatment. Proactive respiratory
microbiological investigations, before any
antibiotic administration at best, are essential
to accurately identify situations in which
antimicrobial treatment can be promptly
withdrawn. For this purpose, routine use of
respiratory multiplex PCR could be a major
asset, contributing to accelerate and possibly
improve bacterial coinfection diagnosis
during severe COVID-19 pneumonia (30). By
reducing unnecessary antibiotic exposure and
subsequent selection pressure, a restrictive
prescription of early empirical antibiotic
treatment could prevent the emergence of
antimicrobial resistance within healthcare
systems (31). This is of major importance
because the incidence of ventilator-associated
lower respiratory tract infections is
particularly high in critically ill patients with
COVID-19 (18, 32).
In addition to those previously
mentioned, our study has some limitations.
First, the study is retrospective, andour results
may not be generalized to other parts of the
world, as most participating centers were
located inFrance. Second, ahighpercentageof
patients were receiving antibiotic treatment
when respiratory samples were collected in
patients with SARS-Cov-2 and those with
influenza pneumonia, which might have
decreased thediagnostic yield and thenumber
of reported positive bacterial cultures.
Therefore, bacterial identification may not
reflect the real rate of bacterial coinfection in
both groups. Third, differentiating bacterial
airway colonization from infection in patients
with a positive microbiological specimenmay
be difficult in patients with SARS-CoV-2 or
influenza pneumonia. Fourth, our definition
of early bacterial identification did not include
bacteria isolated before intubation. Fifth,
numerous data regarding procalcitonin were
missing, and no conclusion could be reached
in our study on its usefulness in the diagnosis
of bacterial coinfection among intubated
patients with COVID-19 (33). Sixth, we did
not collect data on the delay between the onset
of symptoms andhospital admission aswell as
some potentially useful diagnostic tools for
bacterial coinfection, such as leukocyte count,
C-reactive protein, and chest computed
tomographic scanfindings in studypatients. It
would have been interesting to determine
whether superimposed focal consolidation to
the typical ground-glass opacities (34) could
predict the presence of associated bacterial
coinfection. Seventh, no data on antibiotic
deescalation, after initial empirical antibiotic
treatment, was collected in studied patients.
Finally, based on inclusion criteria, only
patients who received invasive mechanical
ventilation for more than 48 hours were
included. Therefore, an immortal time bias
could not be excluded because of early
mortality before 48 hours of mechanical
ventilation. However, this bias would have
occurred in the two study groups.
To conclude, we report a prevalence of
bacterial identificationof9.7%within48hours
after intubation in critically ill patients with
SARS-CoV-2 pneumonia, which is threefold
lower compared with patients with influenza
pneumonia. Our findings encourage the
careful evaluation of the indication of early
empirical antimicrobial treatment in this
population, necessarily guided by a proactive
diagnostic strategy. A strategy limiting
antibiotic treatment to most severe patients,
withARDSor shock, should also be evaluated.
Further studies are needed to better predict
early bacterial coinfection and to assess the
feasibility and safety of antibiotic
stewardship strategies in critically ill patients
with COVID-19.
Author disclosures are available with the text
of this article at www.atsjournals.org.
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Hôpital Duchenne, Boulogne-sur-Mer, France;
Loıc LeGuennec, Departement deNeurologie,
Unite de Medecine Intensive Reanimation
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